Nautilus Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Nautilus Biotechnology
NAUT Stock  USD 1.87  0.02  1.06%   
Analyzing historical trends in various income statement and balance sheet accounts from Nautilus Biotechnology's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nautilus Biotechnology's valuation are summarized below:
Market Capitalization
241.2 M
Earnings Share
(0.50)
There are currently one hundred twenty fundamental ratios for Nautilus Biotechnology that can be evaluated and compared over time across peers in the industry. All traders should check Nautilus Biotechnology's last-minute fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction.
Check Nautilus Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nautilus Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.4 M, Interest Expense of 7 M or Selling General Administrative of 25.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.69. Nautilus financial statements analysis is a perfect complement when working with Nautilus Biotechnology Valuation or Volatility modules.
  
Build AI portfolio with Nautilus Stock
Check out the analysis of Nautilus Biotechnology Correlation against competitors.
For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.

Nautilus Biotechnology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets243 M279.2 M190.3 M
Slightly volatile
Short and Long Term Debt Total46.9 M27.4 M30.9 M
Pretty Stable
Other Current Liabilities2.3 M2.9 M1.2 M
Slightly volatile
Total Current Liabilities5.2 M8.8 M2.8 M
Slightly volatile
Cash60.6 M31.8 M28.7 M
Slightly volatile
Non Current Assets Total94.9 M126.4 M116.6 M
Slightly volatile
Cash And Short Term Investments111.1 M116.9 M76.6 B
Slightly volatile
Common Stock Total Equity13.1 K13.8 K8.3 M
Pretty Stable
Common Stock Shares Outstanding79.5 M144.2 M46.3 M
Slightly volatile
Short Term Investments87.4 M92 M76.5 B
Slightly volatile
Liabilities And Stockholders Equity243 M279.2 M190.3 M
Slightly volatile
Non Current Liabilities Total22.6 M23.7 M34.9 M
Pretty Stable
Other Stockholder Equity291.4 M553.9 M160.9 M
Slightly volatile
Total Liabilities45.7 M30.6 M94.3 M
Slightly volatile
Total Current Assets148 M152.7 M73.7 M
Slightly volatile
Common Stock8.2 K14.9 K4.5 K
Slightly volatile
Property Plant And Equipment Net25.8 M37.2 M12.6 M
Slightly volatile
Accounts Payable1.2 M1.1 M663.9 K
Slightly volatile
Non Currrent Assets Other1.1 M1.4 M744.9 K
Slightly volatile
Property Plant Equipment3.7 M4.3 M2.3 M
Slightly volatile
Warrants112.2 M126.2 M137.8 M
Slightly volatile
Capital Surpluse331.9 M523.6 M160.4 M
Slightly volatile
Capital Lease Obligations28.7 M35 M14.2 M
Slightly volatile
Deferred Long Term Liabilities169.6 K190.8 K208.3 K
Slightly volatile
Property Plant And Equipment Gross46.9 M44.7 M15.3 M
Slightly volatile
Capital Stock11.2 K14.9 K5.1 K
Slightly volatile
Non Current Liabilities Other23 M32.6 M13.4 M
Slightly volatile
Net Working Capital142.6 M112.7 M111.4 M
Slightly volatile
Short Term Debt2.7 M4.7 M2 M
Slightly volatile

Nautilus Biotechnology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization5.4 M5.7 M392.5 M
Slightly volatile
Selling General Administrative25.6 M27.9 M68.9 M
Slightly volatile
Other Operating Expenses64.3 M93.7 M85.9 M
Slightly volatile
Total Operating Expenses61.1 M86.4 M84.1 M
Slightly volatile
Total Other Income Expense Net9.1 M9.6 M393.7 M
Slightly volatile
Research Development32.9 M58 M20.4 M
Slightly volatile
Interest Income6.5 M12.4 M2.9 M
Slightly volatile
Cost Of Revenue4.5 M7.3 M3.3 M
Slightly volatile
Reconciled Depreciation4.4 M7.3 M3.2 M
Slightly volatile
Net Interest Income8.1 M12.4 M3.1 M
Slightly volatile
Selling And Marketing Expenses3.1 M3.5 M3.8 M
Slightly volatile

Nautilus Biotechnology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Cashflows From Financing Activities978.1 K1 M76.9 B
Slightly volatile
Total Cash From Financing Activities978.1 K1 M76.9 B
Slightly volatile
End Period Cash Flow61.3 M32.9 M29 M
Slightly volatile
Stock Based Compensation8 M14.6 M4 M
Slightly volatile
Begin Period Cash Flow22.3 M23.5 M24.6 M
Slightly volatile
Depreciation3.9 M7.3 M2.2 M
Slightly volatile
Dividends Paid42.4 K47.7 K52 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.360.381.1924
Slightly volatile
Payables Turnover3.085.794.5899
Slightly volatile
Cash Per Share1.131.1910.6 K
Slightly volatile
Days Payables Outstanding13065.2189.3274
Slightly volatile
Current Ratio19.0120.01154
Slightly volatile
Capex Per Share0.01850.01950.0985
Slightly volatile
Interest Debt Per Share0.270.283.1444
Very volatile
Debt To Assets0.140.12560.9339
Very volatile
Graham Number29.5533.2436.2851
Slightly volatile
Days Of Payables Outstanding13065.2189.3274
Slightly volatile
Long Term Debt To Capitalization0.580.840.6794
Slightly volatile
Quick Ratio19.0120.01154
Slightly volatile
Net Income Per E B T8.0E-49.0E-40.001
Slightly volatile
Cash Ratio3.964.17131
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.171.191.0927
Very volatile
Debt Ratio0.140.12560.9339
Very volatile

Nautilus Fundamental Market Drivers

Nautilus Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Nautilus Biotechnology Financial Statements

Nautilus Biotechnology shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Nautilus Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Nautilus Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Nautilus Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-853.2 K-810.5 K
Cost Of Revenue7.3 M4.5 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY